Target-specific small-molecule inhibitors, such as the epidermal growth factor receptor (EGFR) inhibitor gefitinib, have been demonstrated to improve the response rate and survival rate compared with chemotherapy[4], which has changed the treatment strategy for EGFR mutation-positive advanced NSCLC patients [5,6] . The gene discussed is EGFR; the disease is non-small cell lung carcinoma.